Results 31 to 40 of about 3,115 (154)

Multivalent Bi‐Specific Nanoerythrosomes: A Two‐Birds‐One‐Stone Approach to Combine Homologous and Active Targeting for Effective Thrombolysis

Small, Volume 22, Issue 47, 21 August 2026.
A multivalent bi‐specific nanoerythrosome (mBiNE@tPA) is developed as a “two‐birds‐one‐stone” platform that simultaneously exploits two principal thrombus components. By integrating erythrocyte membrane‐mediated homologous targeting with cRGD‐based active targeting to activated platelets, mBiNE@tPA achieves enhanced thrombus accumulation, triggered ...
Yu Huang, Yilin Yang, Nicole Henry, Boram Gu, Jiahua Wang, Yuanyuan Guo, Colin Longstaff, Simon A. Thom, Yuehua Li, Xiao Yun Xu, Rongjun Chen   +10 more
wiley   +1 more source

Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke

Neurology International
Objectives: The optimal treatment strategy for ischemic stroke in patients presenting with tandem occlusions of the internal carotid artery remains controversial.
Paweł Latacz, Tadeusz Popiela, Paweł Brzegowy, Bartłomiej Lasocha, Krzysztof Kwiecień, Marian Simka   +5 more
doaj   +1 more source

Repeated Intravenous Thrombolysis in Patients with Recurrent Ischemic Stroke in the Vertebrobasilar Territory

Case Reports in Neurology, 2021
Acute ischemic vertebrobasilar stroke (AIVBS) is usually associated with poor outcome and prognosis and in case of basilar artery occlusion (BAO) with high mortality.
David Černík, Dušan Ospalík, Daniel Šaňák, Filip Cihlář   +3 more
doaj   +1 more source

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, Volume 13, Issue 39, 13 July 2026.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source

Comparison between the effect of intracoronary bolus of tirofiban versus eptifibatide as adjunctive antiplatelet therapy on the outcome of primary coronary intervention in patients with acute anterior ST segment elevation myocardial infarction

The Egyptian Heart Journal, 2011
Background: Primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) has been shown to be the preferred reperfusion strategy.
Tarek M. Zaki, Adel Gamal, Walid A. El Hamady, Sherief Mansour, Tamer M. Abu Arab   +4 more
doaj   +1 more source

Inhibition of platelet adhesion, thrombus formation, and fibrin formation by a potent αIIbβ3 integrin inhibitor from ticks

Research and Practice in Thrombosis and Haemostasis, 2021
Background Ticks puncture the skin of their hosts and secrete saliva, containing antiplatelet proteins, into the blood. Here, we studied disagregin, a potent platelet‐inhibiting protein derived from the salivary glands of Ornithodoros moubata, an African
Danique L. van denKerkhof, Magdolna Nagy, Kanin Wichapong, Sanne L.N. Brouns, Johan W. M. Heemskerk, Tilman M. Hackeng, Ingrid Dijkgraaf   +6 more
doaj   +1 more source

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken, Arnoud W. J. van 't Hof, Jurriën M. ten Berg, Dean J. Kereiakes, Barry S. Coller   +4 more
doaj   +1 more source

Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (RCTs)

Brain and Behavior, Volume 16, Issue 6, June 2026.
Graphical representation of the comparative efficacy and safety of intravenous tirofiban for acute ischemic stroke in randomized controlled trials. ABSTRACT Background: Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes.
Dorothy Lim Bullecer, Cara Mohammed, Julie Anne De Lima Loiola, Mary Gabrielle Te Chy, Samratul Fuadah Ramli, Abimbola Sodiq Hussein, Wasid Bin Showkat, Thahsin Taikadan, Sarika Mutyala, Muhammad Ayyan, Muhammad Aemaz Ur Rehman, Adeel Ahmad, Asma'a Munasar Ali Alsubari   +12 more
wiley   +1 more source

Profound thrombocytopenia after primary exposure to eptifibatide

Drug, Healthcare and Patient Safety, 2010
Nicholas B Norgard, Brian T BadgleyUniversity at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USAAbstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients ...
Nicholas B Norgard, Brian T Badgley
doaj  

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent.
Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli, Anita Deswal, Susan Halli Demeter, Gregory Durm, Anecita Fadol, Alessandra Ferrajoli, Michael G. Fradley, Joerg Herrmann, Borja Ibanez, Sue Koob, Bogda Koczwara, Kasey J. Leger, Jennifer E. Liu, Teresa López‐Fernández, Alexander R. Lyon, N. G. Choon Ta, John Teerlink, Eric H. Yang, Susan Dent, Daniel Lenihan   +22 more
wiley   +1 more source